<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Physical Health ‚Äî MycoMind</title>
  <meta name="description" content="Psilocybin and the body: safety profile, discomfort, tolerance, cardiovascular effects, and anti-inflammatory potential." />
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=DM+Sans:wght@400;500;600;700&display=swap" rel="stylesheet" />
  <link rel="icon" type="image/svg+xml" href="favicon.svg" />
  <link rel="stylesheet" href="style.css" />
</head>
<body>

  <nav class="navbar" id="navbar">
    <div class="nav-container">
      <a href="index.html" class="logo">üçÑ Myco<span>Mind</span></a>
      <button class="nav-toggle" aria-label="Toggle menu">‚ò∞</button>
      <ul class="nav-links">
        <li><a href="mental-health.html">Mental Health</a></li>
        <li><a href="physical-health.html" class="active">Physical Health</a></li>
        <li><a href="how-it-works.html">How It Works</a></li>
        <li><a href="protocols.html">Protocols</a></li>
        <li><a href="science.html">Science</a></li>
        <li><a href="my-recipe.html">My Recipe</a></li>
      </ul>
      <div class="lang-switch">
        <a href="physical-health.html" class="active-lang">EN</a>
        <a href="es/physical-health.html">ES</a>
      </div>
    </div>
  </nav>


  <!-- PHYSICAL BENEFITS -->
  <section class="accordion-section">
    <div class="container">
      <p class="accordion-label">Benefits &amp; Potential</p>

        <details class="accordion-item">
          <summary>Fights inflammation at the root</summary>
          <div class="accordion-body">
            <p>As a 5-HT2A agonist, psilocybin shows <strong>potent anti-inflammatory effects</strong> at sub-hallucinogenic doses ‚Äî reducing TNF-alpha-mediated inflammation in mice (Nichols et al., 2017). This is being clinically investigated for <strong>neuroinflammation</strong> and other inflammatory conditions. These properties may contribute to benefits in depression (neuroinflammation hypothesis), autoimmune conditions, and age-related cognitive decline. More human studies are needed.</p>
          </div>
        </details>

        <details class="accordion-item">
          <summary>It may protect your aging brain</summary>
          <div class="accordion-body">
            <p>Microdosers showed improvements on the finger tap test ‚Äî a measure of psychomotor speed. This effect was <strong>specific to adults aged 55+</strong>, suggesting neuroprotective benefits in ageing populations (Rootman et al., 2022). The Stamets Stack ‚Äî combining psilocybin with Lion's Mane (<em>Hericium erinaceus</em>, which promotes nerve growth factor and neurogenesis in animal models) and Niacin (B3) ‚Äî was associated with even greater psychomotor improvements compared to psilocybin alone. In rodent models, psilocybin promotes <strong>new neural connections and enhanced synaptic plasticity</strong>, with implications for cognitive decline, brain injury recovery, and neurodegenerative disease. It is also being investigated in preclinical Alzheimer's models for its combined anti-inflammatory and neuroplastic effects ‚Äî early results are promising but human trials are in early stages.</p>
          </div>
        </details>

        <details class="accordion-item">
          <summary>Better sleep, fewer cravings</summary>
          <div class="accordion-body">
            <p>Both microdosers and macrodose participants report <strong>decreasing consumption</strong> of alcohol, cannabis, tobacco, caffeine, and psychiatric medications. Users describe feeling less desire for these substances rather than forcing abstinence. A 2024 RCT (Allen et al.) found microdosing increased <strong>sleep duration by ~24 minutes</strong> the night after dosing, including increased REM sleep. Users commonly report improved sleep quality and more vivid dreams.</p>
          </div>
        </details>

        <details class="accordion-item">
          <summary>What users feel in their body</summary>
          <div class="accordion-body">
            <p>Users frequently describe feeling <strong>more physically energised</strong> and alert on microdose days, improved <strong>body awareness</strong> ‚Äî noticing tension, posture, and breathing more easily ‚Äî enhanced enjoyment of physical activities like hiking, yoga, and dancing, reduced <strong>chronic pain perception</strong> (reported anecdotally, not yet studied), and feeling more in tune with hunger, sleep, and natural body rhythms.</p>
          </div>
        </details>

        <details class="accordion-item">
          <summary>Safer than coffee or alcohol</summary>
          <div class="accordion-body">
            <p>A landmark 2010 Dutch study ranked psilocybin as the <strong>lowest-harm substance</strong> out of 19 assessed ‚Äî below alcohol, tobacco, cannabis, and caffeine. No physical dependence has been observed. 21-day daily dosing studies showed <strong>no measurable organ toxicity</strong>, and the largest controlled safety study (King's College London, 2024) found <strong>no serious adverse effects</strong> at clinical doses. Tolerance builds rapidly, making compulsive re-dosing self-limiting. Most users take it infrequently, further reducing any abuse potential ‚Äî psilocybin has <strong>low addiction and dependence liability</strong>.</p>
          </div>
        </details>

    </div>
  </section>

  <!-- PHYSICAL RISKS -->
  <section class="accordion-section">
    <div class="container">
      <p class="accordion-label risk-label">Risks &amp; Concerns</p>
      <div class="accordion-card risk-accordion">

        <details class="accordion-item">
          <summary>Nausea and mild side effects</summary>
          <div class="accordion-body">
            <p>The most common physical challenge (<strong>18%</strong>): mild nausea, headaches, and GI upset. Often caused by the chitin in mushroom material rather than psilocybin itself ‚Äî extracts and teas may reduce these effects. Temporary cardiovascular changes include ~+10‚Äì15 mmHg systolic, ~+5‚Äì10 mmHg diastolic, and ~+5 bpm heart rate. Side effects are generally infrequent, mild, dose-dependent, and short-lasting ‚Äî but a concern for those with hypertension. At moderate to high doses, muscle weakness and lack of coordination are reported but typically resolve within hours.</p>
          </div>
        </details>

        <details class="accordion-item">
          <summary>Dosing is tricky with raw shrooms</summary>
          <div class="accordion-body">
            <p>Tolerance builds quickly via 5-HT2A receptor downregulation ‚Äî effects diminish if dosed daily or more than once per week. This is actually protective against overuse, but means protocols must include off-days. Natural mushrooms <strong>vary significantly in psilocybin content</strong> ‚Äî even within the same species, batch, or individual mushroom. Precise microdosing is challenging with raw material, and accidental perceptible doses are possible.</p>
          </div>
        </details>

        <details class="accordion-item">
          <summary>A heart concern worth watching</summary>
          <div class="accordion-body">
            <p>Psilocybin is a potent 5-HT2B receptor agonist. Long-term use of other 5-HT2B agonists (fenfluramine, MDMA) has been linked to cardiac fibrosis. This has <strong>not been demonstrated for psilocybin in humans</strong>, but no clinical evidence exists either way ‚Äî the theoretical risk warrants caution with frequent, long-term use. More research is needed.</p>
          </div>
        </details>

      </div>
    </div>
  </section>

  <section class="page-sources">
    <div class="container">
      <h3>Sources</h3>
      <ol class="references-list">
        <li>Rootman JM, et al. (2022). "Psilocybin microdosers demonstrate greater observed improvements in mood and mental health." <em>Scientific Reports</em>, 12:11091. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246852/" target="_blank" rel="noopener">PMC9246852</a></li>
        <li>Nichols DE, et al. (2017). Anti-inflammatory effects of serotonergic psychedelics via 5-HT2A agonism.</li>
        <li>Anderson T, et al. (2019). "Psychedelic microdosing benefits and challenges." <em>Harm Reduction Journal</em>, 16(1):43. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617883" target="_blank" rel="noopener">PMC6617883</a></li>
        <li>van Amsterdam J, et al. (2010). Ranking the harm of psychoactive drugs. <em>Lancet</em>.</li>
        <li>Flanagan TW &amp; Nichols CD (2022). Psychedelic anti-inflammatory mechanisms.</li>
        <li>King's College London (2024). Largest controlled psilocybin safety study.</li>
        <li>Allen JWA, et al. (2024). Psychedelic microdosing and sleep ‚Äî RCT findings on sleep duration and REM.</li>
        <li>Pilozzi A, Foster S, Bhatt M (2023). Psychedelics and Alzheimer's disease. Preclinical review.</li>
      </ol>
    </div>
  </section>

  <footer class="footer">
    <div class="container">
      <div class="disclaimer">
        <h4>‚öïÔ∏è Disclaimer</h4>
        <p>This content is for <strong>educational and informational purposes only</strong>. It does not constitute medical advice. Psilocybin mushrooms are controlled substances in most jurisdictions. Always consult a healthcare professional.</p>
      </div>
      <div class="footer-bottom">
        <p class="logo-footer">üçÑ Myco<span>Mind</span></p>
        <p>&copy; 2026 MycoMind. Evidence-based. Not medical advice.</p>
      </div>
    </div>
  </footer>

  <script>
    const navbar = document.getElementById('navbar');
    window.addEventListener('scroll', () => navbar.classList.toggle('scrolled', window.scrollY > 60));
    const toggle = document.querySelector('.nav-toggle');
    const links = document.querySelector('.nav-links');
    toggle.addEventListener('click', () => links.classList.toggle('open'));
    document.querySelectorAll('.nav-links a').forEach(l => l.addEventListener('click', () => links.classList.remove('open')));
  </script>
</body>
</html>
